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Abstract 
Despite decades of research on necrotizing enterocolitis, we still do not fully understand the 
pathogenesis of the disease, how to prevent or how to treat the disease. However, as a result of 
recent significant advances in the microbiology, molecular biology, and cell biology of the 
intestine of premature infants and infants with necrotizing enterocolitis, there is some hope that 
research into this devastating disease will yield some important translation into effective 
prevention, more rapid diagnosis, and novel therapies for the disease.  
 
 
Introduction  
Although necrotizing enterocolitis (NEC) is one of the most common life-threatening surgical 
diseases affecting neonates, we still do not completely understand the pathogenesis or how to 
prevent or treat the disease [1]. Probiotics have not eradicated the disease [2] and the surgical 
outcomes do not appear to have improved over twenty years [3]. The high mortality (around 30% 
for surgical NEC [3] and long-term morbidity [4,5] of survivors mandates urgent research into 
the pathogenesis, diagnosis, prevention and treatment of this devastating disease.  
In this review article, it is not our aim to comprehensively describe all new advances in NEC, but 
instead to describe some areas of progress, focusing wherever possible on clinical studies. 
Epidemiology 
Comprehensive data on NEC incidence and/or surgical outcomes is available from some 
counties, areas, or healthcare systems, including population-based data from Sweden [6] and the 
Vermont-Oxford Network [7]. Until recently, data from the UK has been limited to a survey 
study of 158 NICUs [8], but following the UK National Confidential Enquiry into Patient 
Outcome and Death report in which  gaps in our knowledge about NEC in the UK were 
highlighted [9], two national prospective studies were initiated, one focused on neonatal aspects, 
the other on surgical. In the neonatal study, data were prospectively acquired from 163 English 
neonatal units over 2 years; thus including 118 073 infants, of whom 531 (0·4%) developed 
severe NEC with a mortality of 48% [10]. Interestingly, given the well-known protective effect 
of breast milk, in these infants the absolute risk reduction from human milk compared with 
bovine products was modest. Routinely acquired examination and radiological data from this 
study has also been used to generate a gestational age specific case definition, which has a 
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sensitivity of 66%, a specificity of 94% which the authors suggest should be widely adopted 
[11]. The surgical study, from the British Association of Paediatric Surgeons Congenital 
Anomalies Surveillance System, collected data from 28 neonatal surgical centres over one year 
and showed that 236 infants required surgery for NEC in the UK over one year, and highlighted 
the variation in surgical practices; we eagerly await publication of these data.  In both 
epidemiological studies, infants were identified who died without having surgery. In addition, 
there are those infants who have a laparotomy in which the whole intestine is necrotic prompting 
a decision to withdraw active care. This then leads to the question of whether paediatric surgeons 
should be intervening earlier, and if so, what should be the indications for surgery? A large 
multi-institutional study from the US has attempted to prognosticate NEC infants into low, 
intermediate and high risk on the basis of routinely acquired clinical data including radiological 
and laboratory findings. Their machine-learning model performs well, and the authors suggest 
that dynamic risk stratification will assist in determining the need for additional diagnostic 
testing and guide potential therapies [12].  
Improved diagnostic methods 
Diagnosis of NEC currently relies on a combination of clinical symptoms and signs, and 
radiological features, which are encapsulated in the Bell’s stages of disease, which although 
frequently criticized, are still widely used to describe populations of infants with NEC. For many 
years, researchers have sought plasma, urine or stool biomarkers that would be diagnostic for 
NEC [13]. One of these biomarkers is intestinal fatty acid binding protein (I-FABP), which is 
released into the circulation from damaged enterocytes, and is excreted in urine. It has been 
shown in many studies that I-FABP is increased around the time of development of NEC [14]. 
However, I-FABP concentrations in healthy premature infants are somewhat variable and the 
half-life of I-FABP in plasma is short, so that use of I-FABP concentration in plasma or urine to 
diagnose early NEC is limited. Similarly, although I-FABP can usefully distinguish those infants 
that have more extensive disease and thus require more extensive resection [15], the short half-
life means that unless there is ongoing enterocyte damage, some infants with very extensive 
disease can have paradoxically low I-FABP levels (as all the enterocytes have been lost).  
Recently, biomarker discovery studies of the urinary proteome [16] and peptidome [17] 
have identified proteins and peptides associated with poor outcome (i.e. disease progression). 
Importantly, the biomarkers alone were not able to completely distinguish progressors from non-
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progressors, but were able to when clinical factors were incorporated into the prediction model 
too. This raises the question of the clinical utility of these markers – neither an ELISA (for I-
FABP) nor mass-spectrometry are currently anywhere near point-of-care testing, so whether they 
can be usefully incorporated into medical and surgical decision making, particularly when 
clinical information also has to be taken into account, is uncertain. Circulating cytokines are 
markers of systemic immune status, and pro-inflammatory cytokines have long been known to be 
elevated in NEC. There has been limited information, however, on whether cytokine 
measurements can be useful in diagnosis or risk assessment in NEC. Using a cytokine array only 
IL-10, IL-8 and IL-6 were shown to be significantly higher in surgical NEC than in matched 
controls [18], similar findings on IL-6 and IL-8 being reported by others. The same researchers 
then focussed in on IL-8, which is a chemoattractant for neutrophils and macrophages whose 
intestinal expression has been linked with NEC [19], and showed that IL-8 is a suitable marker 
for preoperative risk assessment, that IL-8 levels obtained within 6 hours prior to surgery 
correlate with the actual intraoperative disease extent [20] and that high levels correlate with 60-
day mortality [21]. Interestingly, although IL-8 is in theory non-specific, whereas I-FABP 
discussed above is specific for the gut, IL-8 may in fact be a better marker than I-FABP [22]. IL-
8 is a routine test in some hospitals, so unlike many laboratory-based biomarkers, might prove to 
be clinically useful, although precise cutoffs and criteria for intervention must be developed. 
Another type of biomarker that has also seen recent interest is the use of analysis of 
volatile organic compounds (VOCs) in stool samples as markers of bacterial metabolism. In one 
pilot study, it was shown that a difference in VOC profile in stool samples between control 
infants and infants with NEC could be used to predict NEC before clinical symptoms [23], and a 
larger study aimed to corroborate these findings is currently underway. Another recent study 
used an ‘electronic nose’ system, in which VOCs are not quantitatively measured, but 
differences in intensity across an array of sensors are used to discriminate samples. The study 
showed that fecal VOC profiles of infants with NEC could be discriminated from controls, from 
2-3 days predating the onset of clinical symptoms [24]. Again, there may be problems in 
utilizing these interesting biomarkers in a clinically useful way, 
 Given that most premature infants will have some form of continual physiological 
monitoring it would be useful to incorporate these measures into early warning tools to predict 
NEC. Some neonatal units are now incorporating sophisticated analysis algorithms into their 
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bedside monitoring, and ultimately these may provide just such a prediction tool. Abnormal heart 
rate characteristics have been suggested as a useful clinical tool to predict sepsis [25], and have 
shown initial promise to predict NEC before clinical diagnosis in a prospective trial setting [26]. 
However, a more recent study in which the same system was used in routine clinical practice 
suggested that abnormal heart rate characteristics have limited ability to detect sepsis [27]. 
Whilst plain radiology remains the primary imaging modality for diagnostic purposes it is 
clear that ultrasound has promise for imaging infants with NEC. Pneumatosis intestinalis and 
portal venous gas are both readily seen during abdominal ultrasound and in fact PVG may be 
detected earlier by US than by plain radiography.  However it is the ability of ultrasound to 
detect infants with more advanced disease and those who may benefit from surgery that has 
attracted greatest attention. Ultrasound permits examination of the intestinal wall in a much more 
detailed way than is possible with plain radiographs and in particular allows an assessment of the 
thickness and perfusion of the intestinal wall and peristalsis. Characteristic perfusion patterns 
have been associated with inflammation, ischaemia and necrosis [28]. Further information that 
can be obtained includes the presence of free intra-abdominal gas and the presence and nature of 
any free intra-abdominal fluid that may be indicative of intestinal perforation. The real challenge 
is to determine whether US can be used to accurately identify infants with NEC who would 
benefit from surgery [28,29]). Further prospective evaluation is undoubtedly needed. 
Near infra-red spectroscopy (NIRS) provides a non-invasive measurement of tissue oxygen 
saturation, which potentially allows a real-time window into intestinal perfusion, which is 
measured as tissue fractional oxygen saturation after taking into account arterial saturation 
concomitantly measured by pulse oximetry. Although one might assume that in NEC infants, 
intestinal perfusion would be lower in infants predisposed to NEC, in fact that cerebral 
oxygenation, rather than intestinal oxygenation, is impaired in the first days of life in infants that 
go on to get NEC, whereas intestinal perfusion is impaired immediately preceding clinical NEC 
[30]. In a further study, although NIRS could not distinguish between definite NEC and absence 
of NEC, it could differentiate between complicated from uncomplicated NEC [31]. 
Encouragingly, these differences in NIRS readings also correlated well with I-FABP levels, thus 
validating the use of NIRS to examine intestinal impairment [32]. 
Pathogenesis 
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The main factors thought to be involved in the pathogenesis of NEC are: intestinal immaturity, 
enteral feeds, the intestinal microbiome, inflammation and local ischaemia and/or reperfusion 
injury. We will briefly discuss recent research in each of these areas below. 
Intestinal immaturity 
The fetal gut develops in an environment where exposure to microbes is limited. Therefore, 
premature infants are exposed to a much greater diversity and quantity of bacteria, viruses and 
fungi. The premature infant gut displays an excessive inflammatory response [19], and toll-like 
receptor 4 seems to play a key role in this inflammatory response ([33] see below). However, a 
difference in inflammatory response is not the only aspect of the premature infant intestine that 
might be affected. The neonatal gut also seems to be more susceptible to intestinal 
ischaemia/reperfusion injury than adult gut [34], and the activity of carbohydrate digestive 
enzymes is significantly lower in preterm intestine than term intestine [35]. Gut motility is also 
different in preterm and term infants [36]. Another potentially important difference between 
premature and term infants is that of maternal separation. Partial separation of mouse pups from 
the mother is enough to induce changes in colonic histology and permeability [37], although the 
relevance of these observations to NEC is unknown. 
Enteral feeding 
Although it has long been known that firstly, NEC predominantly occurs in premature infants 
that have been enterally fed, and secondly that human breast milk is protective towards NEC, we 
do not completely understand how the type of feed interacts with other risk factors. Interestingly, 
the protective effect of breast milk appears to be dose related [38] although as discussed in the 
epidemiology section above, the absolute risk reduction may be modest [10]. A huge array of 
protective factors present in breast milk has been suggested and some of these have been 
suggested as potential preventative measures or treatments (see below). One mechanism by 
which feed components could influence intestinal gene expression is epigenetics, defined as 
‘relating to or arising from non-genetic influences on gene expression’. As epigenetic changes 
frequently involve methylation, they are potentially influenced by diet. A current area of research 
interest is the potential epigenetic effects of breast milk and other enteral feeds [39]. Marked 
epigenetic changes have been observed in the intestine of premature infants [40], and in a pig 
model, enteral feeding has been linked with epigenetic changes causing upregulation of pro-
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inflammatory genes [41]. In addition, the type of enteral feed can also interact with other risk 
factors described below such as the gut microbiome [42] and intestinal blood flow [43]. 
Intestinal microbiome 
While the precise role of bacterial agents in the development of NEC is unclear, several factors 
implicate their involvement. Occasionally NEC is observed to occur in clusters in which 
identical organisms are responsible [44]. However, different organisms are grown from separate 
outbreaks so it cannot be claimed that a single organism is involved in development of NEC. 
Bacterial involvement in the pathogenesis of NEC is also implicated by association; 
endotoxaemia [45,46] and positive blood cultures are common in infants with NEC and the 
gastrointestinal pneumatosis found in NEC contains 30% hydrogen [47], a gas produced solely 
by bacterial metabolism. As long ago as 1975, it was hypothesized that a dysbiosis (imbalance 
between protective microflora and harmful microflora) was involved in the pathogenesis of NEC 
[48]. The recent explosion of interest in the intestinal microbiome, and the availability of high 
throughput pyrosequencing techniques, has led to several relevant research studies in NEC. 
However, such data are very complex, and analysis of these data in a very heterogeneous disease 
like NEC is extremely challenging, especially where both the nosocomial microbiota and their 
measurement methods vary between neonatal units [49].  Nevertheless, studies suggested a loss 
in microbial diversity to occur immediately before NEC onset [50,51]. These preliminary 
findings have been recently corroborated by a large multicentre study [52]. 
Inflammation 
Histologically, there is a massive intestinal inflammatory response in NEC. Some authors have 
even suggested that there may be antenatal precedents to this exaggerated inflammatory 
response, such as chorioamnionitis. A recent systematic review and meta-analysis of available 
studies concluded that chorioamnionitis increased the risk of NEC [53]. Differences in the 
immune response to mucosal damage and the microbiota may also be responsible for the 
exaggerated inflammatory response in NEC (reviewed [54]). Recent studies have highlighted 
such differences, such as those showing that intraepithelial T cell receptor γδ lymphocytes are 
decreased in surgical NEC specimens compared with appropriate controls [55] as are lamina 
propria T regulatory cells [56]. A key player in intestinal inflammation and the response to 
pathogens is TLR4, and recent work has shown that TLR4 signalling is important in the 
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development of NEC [33,57-59]. Intriguingly, TLR4 signalling also links to other factors 
involved in the pathogenesis of NEC, such as the microcirculation ([59] see below). 
Ischaemic injury 
 From early descriptions, ischaemia/reperfusion injury due to relative splanchnic 
hypoperfusion was though to play a part in the pathogenesis of NEC. A primary role for 
intestinal ischaemic damage long fell out of favour, but recently some evidence from both animal 
models and clinical studies has resurrected the potential role of intestinal ischaemia, although 
probably not as the sole initiating factor. Experimental studies have suggested that in NEC, there 
is an impairment in intestinal microcirculation [60-62] which can be improved by direct 
peritoneal resuscitation [63-66].  A potential role for splanchnic hypoperfusion in NEC has been 
suggested from a variety of clinical studies: firstly, there is a decline in mesenteric oxygenation 
when preterm infants are fed during red blood cell transfusion [67]. Secondly, there is increasing 
recognition that an important subset of infants with NEC have congenital cardiac disease that 
may predispose to splanchnic hypoperfusion [68]. Thirdly, several clinical studies have 
suggested that arginine and/or citrulline, amino acids which are important in production of nitric 
oxide and regulation of intestinal blood flow, are decreased in NEC and that supplementation of 
infants with arginine may prevent NEC [69-73]. Finally, a recent histological study of resection 
tissue from infants with NEC has shown that the hypoxia markers hypoxia inducible factor 
1alpha (HIF-1alpha) and glucose transporter 1 (GLUT1) were elevated in NEC, but not in 
spontaneous intestinal perforation or where only a short segment of bowel was affected [74]. 
 
Prevention 
Dietary / pharmacological approaches 
There are several suggested dietary and/or pharmacological approaches to the prevention of 
NEC. Many of these agents are found in human breast milk, for example lactoferrin is a 
glycoprotein that forms part of the innate immune response. A small randomised study in VLBW 
infants found that episodes of sepsis were reduced in infants given oral human lactoferrin but 
none in the treatment or placebo group developed NEC [75]. A randomised controlled trial of 
bovine lactoferrin showed a reduced incidence of NEC compared to controls, and a reduced risk 
of death or progression to stage 3 NEC [76]. Oligosaccharides are complex carbohydrates that 
are components present at much higher concentration in human breast milk than formula. They 
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have been shown to prevent NEC in a rodent model [77], have shown promise in preventing 
NEC in a limited human trial [78] and seem to have generated a recent flurry of activity amongst 
patent lawyers. Another series of compounds that have potential use in preventing NEC is a new 
class of TLR4 inhibitors, which by preventing TLR4 activation may inhibit the inflammatory 
cascade in NEC [79,80]. Of course, probiotics have polarized the neonatal community regarding 
their ability (or not) to prevent NEC [81]. An extensive discussion is beyond the scope of this 
review, and unfortunately we seem no closer to a definitive answer despite large-scale trials such 
as ProPrems [82] and PIPS [83]. Hopefully mechanistic studies (e.g. [84,85] [86,87]), together 
with more detailed understanding of the microbiome and its influence of development of NEC 
(referred to above) may help us to find a way out of this impasse. 
 
Therapy 
Recent evidence from three different research groups has suggested that stem cells are able to 
influence the course of the disease in experimental NEC (reviewed [88]): amniotic fluid stem 
cells [89], mesenchymal stem cells [90,91] and enteric neural stem system cells [92]. In addition 
to the beneficial effects of AFS cells and the conditioned medium from AFS cells, other recent 
evidence highlights the potential role of factors in amniotic fluid in the prevention and/or 
treatment of NEC. Pig and human amniotic fluid, centrifuged so presumed to be largely cell-free, 
have been shown to stimulate proliferation and migration of rat intestinal epithelial cells in vitro 
[93]. In a well-established, clinically relevant model of spontaneous NEC in preterm piglets, 
postnatal minimal enteral feeding with porcine amniotic fluid decreased inflammation together 
with incidence and severity of NEC[94], but had no effect when given later, with full enteral 
feeding, although the beneficial effect during minimal enteral feeding was not consistently 
observed [93] [94]. Another group has shown that enteral delivery of amniotic fluid decreases 
severity of NEC in a mouse model [95]. This effect was shown to be mediated via epidermal 
growth factor (EGF) present in amniotic fluid, and its receptor, epidermal growth factor rector 
(EGFR). In additional experiments, both in vitro and in vivo it was shown that amniotic fluid 
modulates the ability of lipopolysaccharide to trigger toll-like 4- receptor (TLR4) –dependent 
inflammatory signalling, and these effects were mediated via EGF/EGFR[95]. It has also been 
suggested that these protective effects of amniotic fluid are mediated via hepatocyte growth 
factor [96]. 
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Conclusions 
Despite understanding the cardinal features involved in the pathogenesis of NEC, and decades of 
research, we still do not fully understand this devastating disease, how to prevent it or treat it. 
Nevertheless, the broad range and depth of research on the topic does lead to a degree of 
optimism that clinicians and scientists will hopefully be able to deliver novel preventative, 
diagnostic and therapeutic strategies that will translate into improved outcomes. 
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